Larimar Therapeutics, Friedreich's Ataxia
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug
Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin level increases.
Spinocerebellar ataxia type 4 (SCA4), while not widely known due to its rarity, has been a subject of intense investigation.
“Marketresearch.biz reports that the Ataxia market was valued at USD 11,558.3 million in 2023. It is expected to reach USD 20,778.5 million by 2033, with a CAGR of 6.20% during the forecast period ...
(RTTNews) - Larimar Therapeutics, Inc. (LRMR) Tuesday announced that FDA has removed the partial clinical hold placed on its nomlabofusp or CTI-1601, a clinical program targeting treatment of patients ...
Judge Rebecca A. Sanders, chair of the Workers Compensation Appeals Board of the Kansas Department of Labor, Topeka, is the ...
But 15 years ago, he met a patient whom he thought could be the key to solving a decade-long mystery. The patient had ...
Considering taking a vitamin or supplement to treat Cerebellar+Ataxia? Below is a list of common natural remedies used to treat or reduce the symptoms of Cerebellar+Ataxia. Follow the links to ...
The Movement festival kicks off today at Hart Plaza in Detroit. Here's the opening day artist schedule, listed by times. ...
By showing up in droves to view — and buy — painter Al Kittel's colorful art during a reception on May 9, Santa Feans showed their own true colors. I wrote in the May 3 edition of Pasatiempo about ...
When an East Texas cattle operation contacted Texas A&M AgriLife Extension Service cattle specialists in the Texas A&M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback